INV-71 Retinoic acid-related Orphan Receptor (ROR) Gamma Agonist
ROR Gamma Agonist for Immuno-Oncology
Innovimmune’s oral INV-71 RORγ agonists selectively activate the nuclear receptor Retinoic acid receptor-related Orphan Receptor Gamma (RORγ), a master control switch of the immune system driving T helper 17 (Th17) cell and cytotoxic (Tc17) T cell activation. This novel approach to fight cancer combines multiple anti-tumor mechanisms through a single oral agent by modulating RORγ to enhance the body’s immune system to eradicate tumor cells.
Mechanism of Action of INV-71 RORγ Activation
Activating the master control switch RORγ for Immuno-Oncology: Enhancing immune activation & attenuating immune suppression
Scientists at Innovimmune have demonstrated that INV-71 RORγ agonists amplify the Th17 pathway. The anti-tumor treatment efficacy of INV-71 has also been established in mouse in vivo syngeneic models as single agent and in synergy with other immune checkpoint inhibitors. RORγ agonists have the potential as an oral immunotherapy and as an Antibody Drug Conjugate (ADC) attached to a linker as an immunotherapeutic payload designed to kill target cancer cells. The INV-71 program is currently in preclinical development being fast-tracked into IND-enabling development for several solid tumor indications.